Is #cancer drug resistance heritable or plastic? Genetic or non-genetic? How do we tell those apart? We just begun measuring the temporal dynamics of evolving cancers using controllable patient-derived #organoids. We need more experiments+theory! biorxiv.org/content/10.110…

Please help me #RT this 2-years postdoc position #Bioinformatics / #DataScience at the crossing of single-cell #Genomics and #longreads sequencing. With Università di Trieste and Area Science Park in Trieste! Fun work, people and science: more on #LinkedIn linkedin.com/jobs/view/3792…

Now out in Journal of Clinical Oncology, led by the outstanding Biagio Ricciuti, MD PhD and Giuseppe Lamberti, is our group's effort to elucidate mechanisms of resistance to PD-1 #immunotherapy in #lungcancer ascopubs.org/doi/10.1200/JC…

Now online in Cancer Discovery: Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of #LungCancer & Other Malignancies Targetable w/MET Inhibitors Federica Pecci, Seshiru Nakazawa, Pasi Janne, Mark Awad et al. doi.org/10.1158/2159-8… Dana-Farber

Job opportunity! linkedin.com/jobs/view/3924…

Huge congratulations to Nicola Calonaci (Comp Sc) and Eriseld Krasniqi (MD) for driving all this, Marcello Maugeri-Saccà, Stefano Scalera, Biagio Ricciuti, MD PhD, @GiorgiaGandolfi1 and Salvatore Milite for being part of this. Thanks to Università di Trieste and Fondazione AIRC per la ricerca sul cancro for supporting this fabulous work!

Special shoutout to Giulio Caravagna for his invaluable guidance and expertise, to Nicola Calonaci for his vision and tireless dedication and to Marcello Maugeri-Saccà, Stefano Scalera, Biagio Ricciuti, MD PhD, @GiorgiaGandolfi1 and Samantha Militello for their contribution. Università di Trieste IRE ISG IFO Fondazione AIRC per la ricerca sul cancro

🚨Out in JAMA Oncology our effort to determine the association of automatically extracted body composition metrics with #immunotherapy efficacy in patients with metastatic #NSCLC. 👉Skeletal muscle loss & changes in subcutaneous adipose tissue are important dynamic prognostic

Lovely days at ASCO 2024 with cutting-edge science, many talented friends and my terrific mentors Mark Awad & Prof. Andrea Ardizzoni. They still have to teach me how to look at the camera though! P.S. check out our study on TTF-1 expression in LUAD tinyurl.com/7vzez3v8

I think this is a really cool study: evolution and heterogeneity predict long-term outcomes in prostate cancer. Worth emphasising that the lab team were blinded to clinical outcomes until a final great reveal: no risk of over-fitting here! Congrats Andrea Sottoriva and team

Sharing our latest effort out in Clinical Cancer Research! This multicenter study identified a #KEAPness signature that outperforms deleterious #KEAP1 mutations in predicting #ICI efficacy in #NSCLC. A step forward in understanding transcriptional phenocopies of KEAP1 mutations. 🧵1/9

Honored to have our work highlighted in this month’s issue of Annals of Oncology. Many thanks to my mentor Mark Awad, to Jim Smithy, Stephanie Alden & all co-authors, and to patients involved in this study. Also special thanks to the editor-in-chief Tom Powles for selecting it!

Mucinous lung adenocarcinoma (LUAD-Muc) is a WHO-recognized rare subtype of LUAD. Our study in Annals of Oncology aimed to characterize clinicopathologic, genomic, immunophenotypic & transcriptional features differentiating these tumors form other LUADs 1/9 annalsofoncology.org/article/S0923-…

Our paper comprehensively characterizing features and outcomes of patients with mucinous lung adenocarcinomas has just been fully published in Annals of Oncology ESMO - Eur. Oncology Take a look at it here! authors.elsevier.com/c/1kUbL3I2OQir…

Great editorial about mucinous lung adenocarcinomas going through our recently published paper on this non-small lung cancer histology. More effective treatments are remarkably needed. Annals of Oncology ESMO - Eur. Oncology Lukas Bubendorf annalsofoncology.org/article/S0923-… annalsofoncology.org/article/S0923-…

Mucinous lung adenocarcinomas: clinical features & outcomes Annals of Oncology: - Of 4082pts with LUAD, 9.9% LUADMuc - assoc with ⬇️PDL1 expression,⬇️TMB - KRAS, NKX2-1, STK11, SMARCA4, GNAS, ALK+ seen - poorer PFS, OS & ORR to chemo-IO, OncoAlert #LCSM annalsofoncology.org/article/S0923-…

Oltre 80 esperti da tutto il mondo a confronto sul carcinoma polmonare: 🔹 Chirurgia precoce 🔹 Chemoimmunoterapia 🔹 Terapie mirate 🔹 Gestione multidisciplinare 🎯 Al centro: innovazione e qualità di vita. 🎙️ Cappuzzo, Dir. Oncologia Medica 2 #IRE: buff.ly/U7hyo3h

🌸 Grazie ai migliaia di volontari e volontarie che anche quest’anno sono scesi/e in oltre 3900 piazze insieme ad AIRC per distribuire l'Azalea della Ricerca! 🌸 È grazie a voi che avete dedicato il vostro tempo alla nostra iniziativa e grazie alla generosità di chi ci ha

Dr. Biagio Ricciuti, MD, PhD of Dana-Farber's Lowe Center for Thoracic Oncology discusses emerging biomarkers in the periop setting of #nsclc . Clip courtesy of Narjust Florez, MD, FASCO . ASCO #ASCO25 #lcsm #lcam

🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer annalsofoncology.org/article/S0923-… Mark Awad Biagio Ricciuti, MD, PhD